Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00316732
First received: April 20, 2006
Last updated: October 18, 2012
Last verified: October 2012

April 20, 2006
October 18, 2012
October 2004
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00316732 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
An Observational Study to Assess the Effectiveness of Avodart™(Dutasteride)in Subjects With Benign Prostatic Hyperplasia in Day to Day Clinical Practice

This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.

Not Provided
Interventional
Phase 4
Not Provided
  • Benign Prostatic Hyperplasia
  • Prostatic Hyperplasia
  • Procedure: IPSS Questionnaire
  • Procedure: EQ-5D Questionnaire
    Other Names:
    • EQ-5D Questionnaire
    • IPSS Questionnaire
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
530
Not Provided
Not Provided

Inclusion Criteria:

  • Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia).
  • Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH.
  • Patients must only enter the study after the decision to prescribe dutasteride has been undertaken.

Exclusion criteria: None specified

Male
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00316732
103500
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP